NVO
Price
$72.82
Change
+$1.32 (+1.85%)
Updated
Jun 2, 04:59 PM (EDT)
Capitalization
307.42B
65 days until earnings call
TECH
Price
$48.61
Change
+$0.21 (+0.43%)
Updated
Jun 2, 04:59 PM (EDT)
Capitalization
7.59B
71 days until earnings call
Interact to see
Advertisement

NVO vs TECH

Header iconNVO vs TECH Comparison
Open Charts NVO vs TECHBanner chart's image
Novo-Nordisk A/S
Price$72.82
Change+$1.32 (+1.85%)
Volume$49.33K
Capitalization307.42B
Bio-Techne
Price$48.61
Change+$0.21 (+0.43%)
Volume$580.66K
Capitalization7.59B
NVO vs TECH Comparison Chart
Loading...
NVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVO vs. TECH commentary
Jun 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVO is a Buy and TECH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 02, 2025
Stock price -- (NVO: $71.50 vs. TECH: $48.40)
Brand notoriety: NVO and TECH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVO: 106% vs. TECH: 490%
Market capitalization -- NVO: $307.42B vs. TECH: $7.59B
NVO [@Biotechnology] is valued at $307.42B. TECH’s [@Biotechnology] market capitalization is $7.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $307.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVO’s FA Score shows that 2 FA rating(s) are green whileTECH’s FA Score has 1 green FA rating(s).

  • NVO’s FA Score: 2 green, 3 red.
  • TECH’s FA Score: 1 green, 4 red.
According to our system of comparison, NVO is a better buy in the long-term than TECH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVO’s TA Score shows that 5 TA indicator(s) are bullish while TECH’s TA Score has 5 bullish TA indicator(s).

  • NVO’s TA Score: 5 bullish, 3 bearish.
  • TECH’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, TECH is a better buy in the short-term than NVO.

Price Growth

NVO (@Biotechnology) experienced а +6.16% price change this week, while TECH (@Biotechnology) price change was +3.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.16%. For the same industry, the average monthly price growth was +3.07%, and the average quarterly price growth was -0.47%.

Reported Earning Dates

NVO is expected to report earnings on Aug 06, 2025.

TECH is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+6.16% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVO($307B) has a higher market cap than TECH($7.59B). TECH has higher P/E ratio than NVO: TECH (58.31) vs NVO (20.22). NVO YTD gains are higher at: -15.540 vs. TECH (-32.615). NVO has higher annual earnings (EBITDA): 147B vs. TECH (283M). TECH has less debt than NVO: TECH (395M) vs NVO (119B). NVO has higher revenues than TECH: NVO (303B) vs TECH (1.21B).
NVOTECHNVO / TECH
Capitalization307B7.59B4,046%
EBITDA147B283M51,943%
Gain YTD-15.540-32.61548%
P/E Ratio20.2258.3135%
Revenue303B1.21B25,062%
Total Cash41.6BN/A-
Total Debt119B395M30,127%
FUNDAMENTALS RATINGS
NVO vs TECH: Fundamental Ratings
NVO
TECH
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
3
Undervalued
PROFIT vs RISK RATING
1..100
61100
SMR RATING
1..100
1480
PRICE GROWTH RATING
1..100
6464
P/E GROWTH RATING
1..100
9661
SEASONALITY SCORE
1..100
n/a55

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (3) in the Biotechnology industry is in the same range as NVO (26) in the Pharmaceuticals Major industry. This means that TECH’s stock grew similarly to NVO’s over the last 12 months.

NVO's Profit vs Risk Rating (61) in the Pharmaceuticals Major industry is somewhat better than the same rating for TECH (100) in the Biotechnology industry. This means that NVO’s stock grew somewhat faster than TECH’s over the last 12 months.

NVO's SMR Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for TECH (80) in the Biotechnology industry. This means that NVO’s stock grew significantly faster than TECH’s over the last 12 months.

NVO's Price Growth Rating (64) in the Pharmaceuticals Major industry is in the same range as TECH (64) in the Biotechnology industry. This means that NVO’s stock grew similarly to TECH’s over the last 12 months.

TECH's P/E Growth Rating (61) in the Biotechnology industry is somewhat better than the same rating for NVO (96) in the Pharmaceuticals Major industry. This means that TECH’s stock grew somewhat faster than NVO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVOTECH
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
56%
Bullish Trend 4 days ago
70%
Momentum
ODDS (%)
Bullish Trend 4 days ago
65%
Bullish Trend 4 days ago
72%
MACD
ODDS (%)
N/A
Bullish Trend 4 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
66%
Bullish Trend 4 days ago
69%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
66%
Bearish Trend 4 days ago
71%
Advances
ODDS (%)
Bullish Trend 4 days ago
66%
Bullish Trend 4 days ago
70%
Declines
ODDS (%)
Bearish Trend 11 days ago
56%
Bearish Trend 20 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
47%
Bearish Trend 4 days ago
68%
Aroon
ODDS (%)
Bullish Trend 4 days ago
65%
Bullish Trend 4 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
NVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DFLI0.410.04
+11.98%
Dragonfly Energy Holdings Corp
MTA3.220.16
+5.23%
Metalla Royalty & Streaming Ltd
KR68.231.28
+1.91%
Kroger Co (The)
ADMA19.840.07
+0.35%
ADMA Biologics
CTS40.69-0.11
-0.27%
CTS Corp